Isotechnika will now open up the licensing process to companies with a strategic focus in this therapeutic area. The licensing process will be completed based on an accelerated schedule that takes Isotechnika’s interests and current market conditions into account.
Voclosporin is said to be a unique opportunity for partners focused on growing in a very significant market and looking to strengthen their pipeline by adding a late stage product with excellent commercial potential.
Robert Foster, chairman and CEO of Isotechnika, said: “Adding transplant to the list of available indications will greatly strengthen our position and improve the attractiveness of the opportunity to potential partners.”